Wallace Scientific Consulting
David is an experienced medicinal chemist and registered patent agent with over 20 years’ experience in the pharmaceutical industry. He is founder and president of Wallace Scientific Consulting. WSC provides services to early and clinical stage biotech companies, providing prior art/FTO searches and patent application drafting as well as synthetic and medicinal chemistry expertise in the area of small molecule drug discovery. Current and past companies include Samumed, CyanoTech, AnhWalker Therapeutics, Kemin Pharma, EyeCyte, Rempex Pharmaceuticals, Allylix and Mirable. David was also a Scientific Advisory board member and co-founder of Amalyte, Inc., a Bay area biotech company focusing on the treatment of immune and inflammatory diseases. Amalyte was acquired by Kemin Pharma in 2009. He was previously Principal Scientist at Senomyx, Inc., where he served as chemistry group leader of a team focused on the discovery of agonists to G-protein coupled taste receptors. Prior to Senomyx, David held senior scientific and leadership positions at Chugai Pharma, USA, where he contributed to several multidisciplinary research programs directed toward discovery of novel therapies for cancer, cardiovascular, inflammatory, and metabolic diseases. He is an inventor or co-inventor on numerous issued or pending patents. David holds a Ph.D. in Organic Chemistry from the University of California, Davis. He has been a member of the ACS for 29 years and is currently interim councilor of the San Diego Section and associate member of the ACS National Committee on Economic and Professional Affairs (CEPA).